Healthcare of diabetic patient with COVID-19: a practitioner’s view

Česká verzia

Authors: Ján Gajdošík; Zuzana Hlavičková
Authors place of work: Neštátna ambulancia pre dospelých v Nových Zámkoch
Published in the journal: Forum Diab 2022; 11(1): 24-30
Category:

Summary

World´s COVID-19 pandemy affects all spheres of life in the community. It brings many to this time unknown problems, it needs significant changes in community ruling, and mode of community information. Healthcare system needs changes as well, concerning the approach to clientele, as in diagnostics and therapy of the patients, affecting the whole spectrum of coming knowledges and placing them into the practice use.

Keywords:

Primary care – comorbidities – treatment – COVID-19

Zdroje

1. Stejskal F. Covid19 – devět měsíců zkušeností. Jsou přístupy ke kontrole této infekce racionální? Farmakoter Revue 2020; 5(Suppl 1): 8–14. Dostupné z WWW: <https://farmakoterapeutickarevue.cz/cs/novy-koronavirus-sars-cov-2-a-onemocneni-covid-19>.
2. Halata D, Bezdíčková L, Kantorová M et al. Co dělat, když mám příznaky infekce dýchacích cest a co bude následovat. Společnost všeobecného lékařství ČLS JEP: Praha 2020. Dostupné z WWW:<https://www.svl.cz/files/files/COVID-19/Informace-pro-pacienty/Codelat-kdyz-mam-priznaky>.
3. The Royal Australian College of General Practitioners. Managing COVID-19 at home with assistance from your general practice: A guide, action plan and symptom diary for patients. East Melbourne, Vic: RACGP, 2021. Dostupné z WWW: <https://www.racgp.org.au/FSDEDEV/media/documents/Clinical%20Resources/Guidelines/Managingmild-COVID-19-at-home-with-assistance-from-your-GP>.
4. Štandardný postup pre poskytovanie zdravotnej starostlivosti vo všeobecnej ambulancii pre dospelých počas pandémie COVID-19 (verzia 4 platná od dňa 25.11.2021). Dostupné z WWW: <https://www.health.gov.sk/Zdroje?/Sources/Covid-19/Dokumenty/Standardy-covid/SP-PZS-ambulancia-VLD.pdf>.
5. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Dostupné z WWW: <https://www.covid19treatmentguidelines.nih.gov/>.
6. Chrdle A, Dlouhý P, Marek Š. Covid-19: diagnostika a léčba mimo nemocnice 1. Doporučený postup informací dostupných k 15.12.2021 připravený Společností infekčního lékařství ČLS JEP, podpořen výborem Společnosti všeobecného lékařství ČLS JEP). Dostupné z WWW: <https://www.infekce.cz/DPCovid21/DP1-covid-mimo-nemocnice-12–21.pdf>.
7. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239–1242). Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2020.2648>.
8. Carfì A, Bernabei R, Landi F. [Gemelli Against COVID-19 Post-Acute Care Study Group]. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324(6): 603–605. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2020.12603>.
9. Pauk N. Současné možnosti diagnostiky a léčby COVID-19 – zkušenosti z praxe a pro praxi. Jarní interaktivní konference SVL ČLS JEP 25. 10. 2021.
10. Grebenyuk V, Roháčová H, Trojánek M. Klinické a laboratorní nálezy u pacientů s covid-19. Farmakoter Revue 2020; 5(Suppl 1):37–44. Dostupné z WWW: <https://farmakoterapeutickarevue.cz/cs/novy-koronavirus-sars-cov-2-a-onemocneni-covid-19>.
11. Liao D, Zhou F, Luo L et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol 2020; 7(9): e671–e678. Dostupné z DOI: <http://dx.doi.org/10.1016/S2352–3026(20)30217–9>.
12. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(20)30211–7>.
13. WHO – Therapeutics and COVID-19 Living guideline. Dostupné z WWW: <https://apps.who.int/iris/handle/10665/351077>.
14. Usmernenie Ministerstva zdravotníctva Slovenskej republiky k liečbe monoklonálnymi protilátkami (kasirivimab/imdevimab) vo včasnej fáze ochorenia COVID-19 u pacientov s vysokým rizikom ťažkého priebehu ochorenia. Bratislava, 10. december 2021. Číslo: Z106958–2021. Dostupné z WWW: <https://www.health.gov.sk/>.
15. Usmernenie Ministerstva zdravotníctva Slovenskej republiky k liečbe antivirotickým liečivom molnupiravir (Lagevrio 200 mg) pri miernom až stredne ťažkom priebehu ochorenia COVID-19 . Bratislava, 10. december 2021. Číslo: Z106968–2021. Dostupné z WWW: <https://www.health.gov.sk/>.
16. European Medicines Agency. EMA starts evaluating the use of Kineret in adult COVID-19 patients at increased risk of severe respiratory failure. EMA: Amsterdam 2021. Dostupné z WWW: <https://www.ema.europa.eu/en/news/ema-starts-evaluating-use-kineret-adult-covid-19-patients-increased-risk-severe-respiratory-failure>.
17. [European Centre for Disease Prevention and Control An agency of the European Union]. Treatment and pharmaceutical prophylaxis of COVID-19. (Latest update 21 December 2021). Dostupné z WWW: <https://www.ecdc.europa.eu/en/covid-19/latest-evidence/treatment>.
18. [WHO]. Therapeutics and COVID-19: living guideline, 20 November 2020. WHO Regional office for Europe. Dostupné z WWW: <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.1>.
19. [WHO]. COVID-19 Clinical management: living guidance. Geneva: World Health Organization (WHO); 2021 [updated 23 November 2021]. Dostupné z WWW: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021–2>.
20. Langford BJ, So M, Raybardhan S et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020; 26(12): 1622–1629. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmi.2020.07.016>.
21. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021; 27(1): 83–88. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmi.2020.07.041>.
22. Clancy CJ, Schwartz IS, Kula B et al. Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. Open Forum Infect Dis 2021; 8(3): ofab065. Dostupné z DOI: <http://dx.doi.org/10.1093/ofid/ofab065>.
23. Butler CC, Dorward J, Yu L-M et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 2021; 397(10279):1063–1074. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(21)00461-X>.
24. National Institutes of Health (NIH). COVID-19 Treatment Guidelines: Ivermectin. 2021 Dostupné z WWW: <https://www.covid19treatmentguidelines. nih.gov/therapies/antiviral-therapy/ivermectin/>.
25. López-Medina E, López P, Hurtado IC et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA 2021; 325(14): 1426–1435. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2021.3071>.
26. [World Health Organization]. Therapeutics and COVID-19: living guideline. WHO: Geneva 2021. Dostupné z WWW: <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.3>.
27. [MZ SR]. Dostupné z WWW: <https://www.health.gov.sk/>. Clánok Covid-19–27–01–2021-ivermectin).
28. [FLCCC – Front Line COVID-19 Critical Care Alliance]. Prophylaxis & Treatment Protocols for COVID-19. A Guide to the Management of COVID-19. Dostupné z WWW: <https://covid19criticalcare.com/covid-19-protocols>.
29. Janeková E. Ochorenie COVID-19, farmakoterapia a jej úskalia. In: Interakcie a nežiaduce účinky liečiv. Raabe: Bratislava 2021: 1–30. ISBN 978–80–8140–484–9.
30. Hrubiško M, Jeseňák M. Možnosti profylaxie a liečby COVID-19 – prehľad aktuálnych poznatkov. Revue Med Praxi 2021; 19(1): 5–15.
31. Farnoosh G, Akbariqomi M, Badri T et al. Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patietns with COVID-19: A randomized, double-blind clinical trial. Arch Med Res 2022; 53(1): 79–85. Dostupné z DOI: <http://dx.doi.org/10.1016/j.arcmed.2021.06.006>.
32. Darban M, Malek F, Memarian M et al. Efficacy of high dose vitamin C, melatonin and zinc in Iranian patients with acute respiratory sydrome due to Coronavirus infection: A pilot randomized trial. JCMA 2021; 6(2):164–167. Dostupné z DOI: <https://doi.org/10.22037/jcma.v6i2.32182>.
33. Villar J, Confalonieri M, Pastores SM et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome (ARDS) caused by COVID-19. Crit Care Expl 2020; 2(4): e0111. Dostupné z DOI: <http://dx.doi.dorg/10.1097/CCE.0000000000000111>.
34. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020; 6; 324(13): 1330–1341. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2020.17023>.
35. I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19. Dostupné z WWW: <https://covid19criticalcare. com/i-mask-prophylaxis-treatment-protocol/>.